Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | RAB9A | P51151 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.61 |
| ▸ | F10 | P00742 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.59 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15233664 | 0.91 | F10 (0.72) | MAPTNPC1RAB9ASMN1; SMN2F10 | |
| SCHEMBL15233666 | 0.89 | MEN1 (0.63) | MAPTNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL4481689 | 0.83 | ALDH1A1 (0.57) | MAPTNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL314038 | 0.82 | F10 (0.77) | NPC1RAB9ASMN1; SMN2F10MEN1 | |
| SCHEMBL8820811 | 0.82 | SMN1; SMN2 (0.76) | MAPTNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL11826733 | 0.82 | RAB9A (0.65) | MAPTNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL29175052 | 0.82 | NPC1 (0.65) | MAPTNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL1026559 | 0.82 | ALDH1A1 (0.59) | MAPTNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL23352868 | 0.81 | RAB9A (0.70) | MAPTNPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL2935687 | 0.81 | MEN1 (0.69) | MAPTNPC1RAB9ASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102627-A1 | Acridines As Inhibitors Of Haspin And DYRK Kinases | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2011127406-A2 | ACRIDINES AS INHIBITORS OF HASPIN AND DYRK KINASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102627-A1 | Acridines As Inhibitors Of Haspin And DYRK Kinases | HASPIN, MAP3K6, DAPK2 | MAPT 825/4885NPC1 2875/4885RAB9A 1554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.